Gilead Sciences, Inc. with ticker code (GILD) have now 24 market analysts covering the stock. The analyst consensus now points to a rating of ‘buy’. The target price High/Low ranges between $116.00 and $69.00 and has a mean target at $89.29. Given that the stocks previous close was at $80.37 and the analysts are correct then there would likely be a percentage uptick in value of 11.1%. The 50 day moving average now sits at $78.16 and the 200 day moving average is $78.25. The market capitalization for the company is 101.10B. The current share price for the company is: $81.14 USD
The potential market cap would be $112,324,853,251 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 17.37, revenue per share of $21.90 and a 9.21% return on assets.
Gilead Sciences, Inc. is a biopharmaceutical company. The Company is engaged in advancing medicines to prevent and treat life-threatening diseases, including human immunodeficiency virus (HIV), viral hepatitis and cancer. The Company offers products in HIV, Onocolgy, Liver Disease, Vekulaery, and Other. Under HIV, it offers Biktarvy, Complera/Eviplera, Genvoya, Odefsey, Stribild, and Truvada. Its Veklury (remdesivir) is a nucleotide analog RNA polymerase inhibitor indicated for the treatment of coronavirus disease 2019 (COVID-19). Under oncology it offers cell therapy containing Tecartus and Yescarta. Under this Liver Disease consists of Chronic hepatitis C virus (HCV) (Ledipasvir/Sofosbuvir and Sofosbuvir/Velpatasvir) and Chronic hepatitis B virus (HBV) / hepatitis delta virus (HDV) (Vemlidy and Viread). The Company’s other products include AmBisome and Letairis. It also operates a portfolio of small molecule inhibitors targeting PARP1 for oncology and MK2 for inflammatory diseases.
